← All Compounds
Mechanism Selective growth hormone secretagogue peptide. Binds ghrelin/GHS receptors in the pituitary to stimulate GH release without significantly affecting cortisol, prolactin, or ACTH levels. Half-Life Approximately 2 hours Route subcutaneous Frequency 2-3x daily
FDA Category Research peptide (FDA Category 2) Reclassification pending Date Restricted 2023-09-29 Announced Return 2026-02-27
Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
Ipamorelin
Cat 2 → Pending Cat 1GH Secretagogue · Research peptide (multiple suppliers)
Selective growth hormone secretagogue peptide that stimulates GH release via ghrelin/GHS receptors without significantly affecting cortisol, prolactin, or ACTH levels.
About
Clinical Dosing
100-300 mcg2-3x daily
Not FDA-approved. Currently Category 2 (restricted). Pending return to Category 1. Often paired with CJC-1295 (no DAC).
Dosing based on small human studies or early-phase trials. Not established by Phase 3 evidence.
Regulatory Status
Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.
View full regulatory timeline →Titration Protocols
Research Dosing Protocol
Source: Raun et al., European Journal of Endocrinology, 1998
| Dose | Duration | Draw (2 mg vial in 2mL) | Notes |
|---|---|---|---|
| 200 mcg | Maintenance | 0.20 mL (20 units) | Standard dose 2-3x/day, often combined with CJC-1295 |
Available Vial Sizes
2 mg
2 mg vial
5 mg
5 mg vial
Citations
- [1]Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology, 139(5), 552-561. Link(Reviewed: 2026-02-27)